CS
EUCRU

Clear Street’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Clear Street’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,740
Closed -$28.4K – 1581
2023
Q1 		$28.4K Buy
2,740
+100
+4% +$1.01K ﹤0.01% 323
2022
Q4 		$26K Buy
+2,640
New +$26.3K ﹤0.01% 343
2022
Q1 		– Sell
-8,980
Closed -$90K – 573
2021
Q4 		$90K Buy
+8,980
New +$90.2K ﹤0.01% 72

Clear Street's EUCRU Position: Q2 2023 in Review

Clear Street sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q2 2023, closing a stake of 2,740 shares — an estimated $28.4K sold.

Clear Street first reported a position in EUCRU in Q4 2021 and held it in 3 quarters. The position peaked at $90K in Q4 2021. 0 funds tracked by Wall St. Rank hold EUCRU as of Q2 2023.

  • Clear Street reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q2 2023 after selling out during the quarter.
  • Clear Street sold 2,740 Eucrates Biomedical Acquisition Corp. Unit shares in Q2 2023, an estimated $28.4K.
  • Clear Street first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2021 and held it in 3 quarters.
  • Clear Street's Eucrates Biomedical Acquisition Corp. Unit position peaked at $90K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q2 2023.

Based on Clear Street's 13F filing for Q2 2023, filed 14 Aug 2023.